GT Biopharma, Inc.

GT Biopharma (GTBP) showed no cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting a quiet recent period on the compliance front. However, low signal in a 3-month window does not indicate low structural risk—biotech companies face persistent dilution pressure and equity financing cycles that require deeper historical context. The full $49 Report extends analysis back 12 months, calculates dilution risk scores, maps financing history, and flags AI-detected anomalies in capital structure and officer transactions. The full $49 Report adds that deeper 12-month lens, dilution quantification, and capital risk signals that a short window cannot capture.